Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: An open-label extension study

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 3, 2013, Pages 194-199

  Harfterkamp, Myriam ^a   Buitelaar, Jan K ^b,c   Minderaa, Ruud B ^a   Van De Loo Neus, Gigi ^b   Van Der Gaag, Rutger Jan ^b   Hoekstra, Pieter J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INFLUENZA; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VOMITING;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 84876695871     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0012     Document Type: Article

References (16)

1. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D: Once-daily atomoxetine for adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 29: 44-50, 2009.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
3. Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J: A randomized, double-blind study of continuation treatment for attention-deficit/ hyperactivity disorder after 1 year. Biol Psychiatry 61: 694-699, 2007.
4. Donnelly C, Bangs M, Trzepacz P, Ling J, Shuyu Z, Witte MM, Ball SG, Spencer TJ: Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 48: 2, 2009.
5. DuPaul GJ, Anastopoulos AD, Power TJ, Reid R, Ikeda MJ, McGoey KE: Parent ratings of attention-deficit/hyperactivity disorder symptoms: factor structure and normative data. J Psychopathol Behav Assess 20: 3-102, 1998.
6. Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5: 107-115, 2001.
7. Harfterkamp MA, Loo-Neus van de G, Minderaa RB, Gaag van der RJ, Escobar R, Schacht A, Pamulapati S, Hoekstra P: A randomized double-blind study of atomoxetine versus placebo for ADHD symptoms in children with ASD. J Am Acad Child Adolesc Psychiatry 51: 733-741, 2012.
8. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL: Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45: 919-927, 2006.
9. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 159: 1896-1901, 2002.
10. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J: Relapse prevention in pediatric patients with adhd treated with atomoxetine: A randomized, double-blind, placebo-controlled study. J Am Acad Child Adolescent Psychiatry; 43: 896-904, 2004.
11. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, the Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: A randomized placebo-controlled, doseresponse study. Pediatrics 108: 5, 2001.
12. Montoya A, Hervas A, cardo E, Arigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-näve children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin 25: 2745-2754, 2009.
13. Rutter M, Le Couteur A, Lord C: Autism Diagnostic Interview Revised. Manual. Los Angeles: Western Psychological Services; 2003.
14. Svanborg P, Thernlund G, Gustafsson PA, Hagglof B, Poole L, Kadesjo B: Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: A randomized, double blind, placebo-controlled study in stimulant-näve Swedish children and adolescents. Eur Child Adolesc Psychiatry 18: 240-249, 2009.
15. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Boras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ: A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Child Adolesc Psychiatry 44: 647-655, 2005.
16. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, Feldman PD, Levine LR. Long-term atomoxetine treatment in adolescents with attention deficit/hyperactivity disorder. J Pediatr 149, 112-119, 2006.